Menu

Partial Reprogramming Offers a Way to Generate High Volumes of Progenitor-Like Cells

Activating genes for reprogramming factors for a short time transforms large numbers of differentiated cells into multipotent forms that could be useful for cell-based therapies.

Nov 30, 2017
Abby Olena

Hollow iPL colonyLILY GUOThe promise of cell-based therapy is limited by the challenge of generating large enough numbers of the correct type of cells. But a strategy called interrupted reprogramming could help overcome this limitation. In study published today (November 30) in Stem Cell Reports, researchers in Canada subjected mouse lung cells to reprogramming factors for short periods of time, which nudged the cells toward a multipotent, progenitor-like state capable of dividing exponentially to give rise to large numbers of cells, but stopped short of pluripotency.

Coauthor Thomas Waddell, a thoracic surgeon and researcher at the University of Toronto, explains that in the past, researchers have focused on the final product of cellular reprogramming, the induced pluripotent stem cell (iPSC), but that the process of generating iPSCs can be time-consuming and expensive. “We’re interested in the idea that reprogramming could become something other than the two extremes, skin cell [and] pluripotent cell,” he says. “In between there’s actually a lot of interesting biology that is potentially available for therapeutic optimization.”

Waddell and colleagues isolated club cells—a population of both terminally differentiated and variant cells, which proliferate in response to injury—from the lungs of adult mice. They sorted the cells to collect those that appeared to contain only mature club cells that did not proliferate extensively in vitro.

Transgenes in the mice allowed the researchers to administer doxycycline to activate the four genes commonly used to generate iPSCs. Cells treated with the drug proliferated exponentially and formed colonies, while untreated cells did not form colonies.

The authors determined that to make multipotent cells, rather than full iPSCs, the ideal duration of doxycycline exposure was three weeks. This time period generated induced progenitor-like (iPL) cells that expanded quickly and had the ability to form colonies, but did not lead to more pluripotent cells induced by longer treatments. The cells increased exponentially in number by about 30 fold, in contrast to methods of generating iPSCs, which often have low yields.

Mature Club cells derived from iPL cells LILY GUOThese iPL cells were more likely to develop into different types of lung cells than cells treated with the drug for longer periods. And when they removed doxycycline, the iPL cells reverted back to a club-cell phenotype, suggesting that they maintain their lineage commitment. The cells were also capable of replacing lung cells in a mouse model of cystic fibrosis, and did not cause teratomas.

The work is “innovative and could be of interest for cell therapies for lung disease. For people in the lung field it will be very exciting,” says Bernard Thebaud, a physician and researcher at the Ottawa Hospital Research Institute in Canada who did not participate in the study. “The concept could also be applied to cells outside of the lung,” he adds.

“We do think it’s applicable to other cell types,” agrees Waddell, whose team is already testing the technique in other lung cells. Their collaborators are also exploring the utility of the strategy in the pancreas.

“The question for me is, does this partial reprogramming that they’ve subjected the cells to really add any reasonable benefit to what the cells are capable of doing at baseline in the proper conditions?” says Andrew Vaughan, who studies lung stem and progenitor cells at the University of Pennsylvania School of Veterinary Medicine and did not participate in the work. Because club cells have endogenous proliferative capacity and other groups have had success growing them in vitro, he explains, it is not clear to what degree interrupted reprogramming represents an advance.

Vaughan says that there is a need for strategies that will allow for the generation of large numbers of cells and maintenance of those cells for long periods of time in culture, especially when starting with human cells. “If partial reprogramming were to allow us to . . . expand the cells indefinitely, especially if they were derived from the patients themselves, then you’d be looking at a real step forward in potential cell-based therapy applications,” he says.

L. Guo et al., “Generation of induced progenitor-like cells from mature epithelial cells using interrupted reprogramming,” Stem Cell Reports, doi:10.1016/j.stemcr.2017.10.022, 2017.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.